Adrian Bickerstaffe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adrian Bickerstaffe has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- John Llewelyn Hopper
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia
3 shared publications - Jon Emery
Nanyang Technological University 5 Singapore
3 shared publications - Kelly-Anne Phillips
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
3 shared publications - Phyllis Butow
Psycho-Oncology Co-operative Research Group (PoCoG), School of Psychology, The University of Sydney, Sydney, Australia
3 shared publications - Alison H. Trainer
Department of Genomic Medicine, The Royal Melbourne Hospital, Melbourne, Victoria, Australia
2 shared publications - Antonis C. Antoniou
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge , Cambridge CB1 8RN
2 shared publications
Latest Publications
- Open Access
- 8 December 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Towards an ASQ-TRAK app: A rapid scoping review of enablers and barriers to mHealth development and implementation with Aboriginal and Torres Strait Islander peoples (Preprint)
BACKGROUND The ASQ-TRAK (Ages and Stages Questionnaire – Talking about Raising Aboriginal Kids) is the only culturally responsive developmental screening tool validated for Aboriginal and Torres Strait Islander children. Digitization of the ASQ-TRAK may be an opportunity to enhance its accessibility and reach. However, limited information exists on how to develop mHealth apps in partnership with Aboriginal and Torres Strait Islander communities. OBJECTIVE This scoping review identified mHealth apps developed for Aboriginal and Torres Strait Islander people. It examined key enablers and barriers to the development and implementation of these mHealth apps. METHODS A structured database search was conducted (Mar 2025). Studies that described or evaluated app development or implementation with Aboriginal and Torres Strait Islander peoples were screened against predefined eligibility criteria. Data extraction included bibliographic details, methodological characteristics, and app-specific information. Enablers and barriers were mapped to an emergent best practice framework for eHealth with Aboriginal and Torres Strait Islander peoples. RESULTS 22 studies published between 2015 and 2025, describing 11 apps, were included. Key enablers included Aboriginal-led research, culturally safe co-design approaches, strong partnerships, and integration of local languages and cultural elements. Barriers encompassed research design limitations, workforce constraints, technical issues, and challenges in sustained implementation. Critical gaps emerged in reporting organizational infrastructure, app governance arrangements, privacy protections, and data management practices. CONCLUSIONS This review revealed a critical gap between developing apps for research purposes and creating sustainable, community-controlled mHealth tools for real-world implementation. Future mHealth initiatives should prioritize community ownership, planning for sustainable implementation, integration with existing care and infrastructure, and transparent reporting. CLINICALTRIAL n/a
- 8 December 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessTowards an ASQ-TRAK app: A rapid scoping review of enablers and barriers to mHealth development and implementation with Aboriginal and Torres Strait Islander peoples (Preprint)
BACKGROUND The ASQ-TRAK (Ages and Stages Questionnaire – Talking about Raising Aboriginal Kids) is the only culturally responsive developmental screening tool validated for Aboriginal and Torres Strait Islander children. Digitization of the ASQ-TRAK may be an opportunity to enhance its accessibility and reach. However, limited information exists on how to develop mHealth apps in partnership with Aboriginal and Torres Strait Islander communities. OBJECTIVE This scoping review identified mHealth apps developed for Aboriginal and Torres Strait Islander people. It examined key enablers and barriers to the development and implementation of these mHealth apps. METHODS A structured database search was conducted (Mar 2025). Studies that described or evaluated app development or implementation with Aboriginal and Torres Strait Islander peoples were screened against predefined eligibility criteria. Data extraction included bibliographic details, methodological characteristics, and app-specific information. Enablers and barriers were mapped to an emergent best practice framework for eHealth with Aboriginal and Torres Strait Islander peoples. RESULTS 22 studies published between 2015 and 2025, describing 11 apps, were included. Key enablers included Aboriginal-led research, culturally safe co-design approaches, strong partnerships, and integration of local languages and cultural elements. Barriers encompassed research design limitations, workforce constraints, technical issues, and challenges in sustained implementation. Critical gaps emerged in reporting organizational infrastructure, app governance arrangements, privacy protections, and data management practices. CONCLUSIONS This review revealed a critical gap between developing apps for research purposes and creating sustainable, community-controlled mHealth tools for real-world implementation. Future mHealth initiatives should prioritize community ownership, planning for sustainable implementation, integration with existing care and infrastructure, and transparent reporting. CLINICALTRIAL n/a
- Open Access
- 23 January 2023
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 73 (733) , e556-e565
The Colorectal cancer RISk Prediction (CRISP) trial: a randomised controlled trial of a decision support tool for risk-stratified colorectal cancer screening
Background: A risk-stratified approach to colorectal cancer (CRC) screening could result in a more acceptable balance of benefits and harms, and be more cost-effective.Aim: To determine the effect of a consultation in general practice using a computerised risk assessment and decision support tool (Colorectal cancer RISk Prediction, CRISP) on risk-appropriate CRC screening.Design and setting: Randomised controlled trial in 10 general practices in Melbourne, Australia, from May 2017 to May 2018.Method: Participants were recruited from a consecutive sample of patients aged 50–74 years attending their GP. Intervention consultations included CRC risk assessment using the CRISP tool and discussion of CRC screening recommendations. Control group consultations focused on lifestyle CRC risk factors. The primary outcome was risk-appropriate CRC screening at 12 months.Results: A total of 734 participants (65.1% of eligible patients) were randomised (369 intervention, 365 control); the primary outcome was determined for 722 (362 intervention, 360 control). There was a 6.5% absolute increase (95% confidence interval [CI] = −0.28 to 13.2) in risk-appropriate screening in the intervention compared with the control group (71.5% versus 65.0%; odds ratio [OR] 1.36, 95% CI = 0.99 to 1.86,P= 0.057). In those due CRC screening during follow-up, there was a 20.3% (95% CI = 10.3 to 30.4) increase (intervention 59.8% versus control 38.9%; OR 2.31, 95% CI = 1.51 to 3.53,P<0.001) principally by increasing faecal occult blood testing in those at average risk.Conclusion: A risk assessment and decision support tool increases risk-appropriate CRC screening in those due screening. The CRISP intervention could commence in people in their fifth decade to ensure people start CRC screening at the optimal age with the most cost-effective test.
- 23 January 2023
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 73 (733) , e556-e565
Open AccessThe Colorectal cancer RISk Prediction (CRISP) trial: a randomised controlled trial of a decision support tool for risk-stratified colorectal cancer screening
Background: A risk-stratified approach to colorectal cancer (CRC) screening could result in a more acceptable balance of benefits and harms, and be more cost-effective.Aim: To determine the effect of a consultation in general practice using a computerised risk assessment and decision support tool (Colorectal cancer RISk Prediction, CRISP) on risk-appropriate CRC screening.Design and setting: Randomised controlled trial in 10 general practices in Melbourne, Australia, from May 2017 to May 2018.Method: Participants were recruited from a consecutive sample of patients aged 50–74 years attending their GP. Intervention consultations included CRC risk assessment using the CRISP tool and discussion of CRC screening recommendations. Control group consultations focused on lifestyle CRC risk factors. The primary outcome was risk-appropriate CRC screening at 12 months.Results: A total of 734 participants (65.1% of eligible patients) were randomised (369 intervention, 365 control); the primary outcome was determined for 722 (362 intervention, 360 control). There was a 6.5% absolute increase (95% confidence interval [CI] = −0.28 to 13.2) in risk-appropriate screening in the intervention compared with the control group (71.5% versus 65.0%; odds ratio [OR] 1.36, 95% CI = 0.99 to 1.86,P= 0.057). In those due CRC screening during follow-up, there was a 20.3% (95% CI = 10.3 to 30.4) increase (intervention 59.8% versus control 38.9%; OR 2.31, 95% CI = 1.51 to 3.53,P<0.001) principally by increasing faecal occult blood testing in those at average risk.Conclusion: A risk assessment and decision support tool increases risk-appropriate CRC screening in those due screening. The CRISP intervention could commence in people in their fifth decade to ensure people start CRC screening at the optimal age with the most cost-effective test.
- Open Access
- 21 June 2020
- Published by Wiley in Australasian Journal on Ageing
- Vol. 39 (S1) , 40-48
‘That might be a bit sexy for somebody your age’: Older adult sexual health conversations in primary care
Background: Many older adults are sexually active, and STIs are rising amongst this cohort. In primary care, sexual health discussions are limited as health‐care practitioners commonly assume older patients aged 60+ are not sexually active or are unwilling to discuss sex. Studies have either examined patient or clinician views, but not both.Objective: This study investigates sexual health discussions in general practice. It is unique in that it sought perspectives of different groups: older patients, health‐care professionals and key informants.Results: Qualitative interviews revealed that older patients expect clinicians to bring up sexual concerns, whereas clinicians prefer older patients to do so. A simple electronic solution to circumvent this impasse was suggested and discussed.Conclusions: Older adults would like to discuss sexual concerns with their health‐care providers. Given the rising rates of STIs in later life, sexual health discussions with older patients must become part of routine care.
- 21 June 2020
- Published by Wiley in Australasian Journal on Ageing
- Vol. 39 (S1) , 40-48
Open Access‘That might be a bit sexy for somebody your age’: Older adult sexual health conversations in primary care
Background: Many older adults are sexually active, and STIs are rising amongst this cohort. In primary care, sexual health discussions are limited as health‐care practitioners commonly assume older patients aged 60+ are not sexually active or are unwilling to discuss sex. Studies have either examined patient or clinician views, but not both.Objective: This study investigates sexual health discussions in general practice. It is unique in that it sought perspectives of different groups: older patients, health‐care professionals and key informants.Results: Qualitative interviews revealed that older patients expect clinicians to bring up sexual concerns, whereas clinicians prefer older patients to do so. A simple electronic solution to circumvent this impasse was suggested and discussed.Conclusions: Older adults would like to discuss sexual concerns with their health‐care providers. Given the rising rates of STIs in later life, sexual health discussions with older patients must become part of routine care.
- Open Access
- 7 November 2018
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 2 (2) , e24
The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing
Background: iPrevent estimates breast cancer (BC) risk and provides tailored risk management information. Objective: The objective of this study was to assess the usability and acceptability of the iPrevent prototype. Methods: Clinicians were eligible for participation in the study if they worked in primary care, breast surgery, or genetics clinics. Female patients aged 18-70 years with no personal cancer history were eligible. Clinicians were first familiarized with iPrevent using hypothetical paper-based cases and then actor scenarios; subsequently, they used iPrevent with their patients. Clinicians and patients completed the System Usability Scale (SUS) and an Acceptability questionnaire 2 weeks after using iPrevent; patients also completed measures of BC worry, anxiety, risk perception, and knowledge pre- and 2 weeks post-iPrevent. Data were summarized using descriptive statistics. Results: The SUS and Acceptability questionnaires were completed by 19 of 20 clinicians and 37 of 43 patients. Usability was above average (SUS score >68) for 68% (13/19) clinicians and 76% (28/37) patients. The amount of information provided by iPrevent was reported as “about right” by 89% (17/19) clinicians and 89% (33/37) patients and 95% (18/19) and 97% (36/37), respectively, would recommend iPrevent to others, although 53% (10/19) clinicians and 27% (10/37) patients found it too long. Exploratory analyses suggested that iPrevent could improve risk perception, decrease frequency of BC worry, and enhance BC prevention knowledge without changing state anxiety. Conclusions: The iPrevent prototype demonstrated good usability and acceptability. Because concerns about length could be an implementation barrier, data entry has been abbreviated in the publicly available version of iPrevent.
- 7 November 2018
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 2 (2) , e24
Open AccessThe iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing
Background: iPrevent estimates breast cancer (BC) risk and provides tailored risk management information. Objective: The objective of this study was to assess the usability and acceptability of the iPrevent prototype. Methods: Clinicians were eligible for participation in the study if they worked in primary care, breast surgery, or genetics clinics. Female patients aged 18-70 years with no personal cancer history were eligible. Clinicians were first familiarized with iPrevent using hypothetical paper-based cases and then actor scenarios; subsequently, they used iPrevent with their patients. Clinicians and patients completed the System Usability Scale (SUS) and an Acceptability questionnaire 2 weeks after using iPrevent; patients also completed measures of BC worry, anxiety, risk perception, and knowledge pre- and 2 weeks post-iPrevent. Data were summarized using descriptive statistics. Results: The SUS and Acceptability questionnaires were completed by 19 of 20 clinicians and 37 of 43 patients. Usability was above average (SUS score >68) for 68% (13/19) clinicians and 76% (28/37) patients. The amount of information provided by iPrevent was reported as “about right” by 89% (17/19) clinicians and 89% (33/37) patients and 95% (18/19) and 97% (36/37), respectively, would recommend iPrevent to others, although 53% (10/19) clinicians and 27% (10/37) patients found it too long. Exploratory analyses suggested that iPrevent could improve risk perception, decrease frequency of BC worry, and enhance BC prevention knowledge without changing state anxiety. Conclusions: The iPrevent prototype demonstrated good usability and acceptability. Because concerns about length could be an implementation barrier, data entry has been abbreviated in the publicly available version of iPrevent.
- Open Access
- 25 January 2018
- Published by JMIR Publications Inc. in JMIR Preprints
The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing (Preprint)
BACKGROUND iPrevent estimates breast cancer (BC) risk and provides tailored risk management information. OBJECTIVE The objective of this study was to assess the usability and acceptability of the iPrevent prototype. METHODS Clinicians were eligible for participation in the study if they worked in primary care, breast surgery, or genetics clinics. Female patients aged 18-70 years with no personal cancer history were eligible. Clinicians were first familiarized with iPrevent using hypothetical paper-based cases and then actor scenarios; subsequently, they used iPrevent with their patients. Clinicians and patients completed the System Usability Scale (SUS) and an Acceptability questionnaire 2 weeks after using iPrevent; patients also completed measures of BC worry, anxiety, risk perception, and knowledge pre- and 2 weeks post-iPrevent. Data were summarized using descriptive statistics. RESULTS The SUS and Acceptability questionnaires were completed by 19 of 20 clinicians and 37 of 43 patients. Usability was above average (SUS score >68) for 68% (13/19) clinicians and 76% (28/37) patients. The amount of information provided by iPrevent was reported as “about right” by 89% (17/19) clinicians and 89% (33/37) patients and 95% (18/19) and 97% (36/37), respectively, would recommend iPrevent to others, although 53% (10/19) clinicians and 27% (10/37) patients found it too long. Exploratory analyses suggested that iPrevent could improve risk perception, decrease frequency of BC worry, and enhance BC prevention knowledge without changing state anxiety. CONCLUSIONS The iPrevent prototype demonstrated good usability and acceptability. Because concerns about length could be an implementation barrier, data entry has been abbreviated in the publicly available version of iPrevent.
- 25 January 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing (Preprint)
BACKGROUND iPrevent estimates breast cancer (BC) risk and provides tailored risk management information. OBJECTIVE The objective of this study was to assess the usability and acceptability of the iPrevent prototype. METHODS Clinicians were eligible for participation in the study if they worked in primary care, breast surgery, or genetics clinics. Female patients aged 18-70 years with no personal cancer history were eligible. Clinicians were first familiarized with iPrevent using hypothetical paper-based cases and then actor scenarios; subsequently, they used iPrevent with their patients. Clinicians and patients completed the System Usability Scale (SUS) and an Acceptability questionnaire 2 weeks after using iPrevent; patients also completed measures of BC worry, anxiety, risk perception, and knowledge pre- and 2 weeks post-iPrevent. Data were summarized using descriptive statistics. RESULTS The SUS and Acceptability questionnaires were completed by 19 of 20 clinicians and 37 of 43 patients. Usability was above average (SUS score >68) for 68% (13/19) clinicians and 76% (28/37) patients. The amount of information provided by iPrevent was reported as “about right” by 89% (17/19) clinicians and 89% (33/37) patients and 95% (18/19) and 97% (36/37), respectively, would recommend iPrevent to others, although 53% (10/19) clinicians and 27% (10/37) patients found it too long. Exploratory analyses suggested that iPrevent could improve risk perception, decrease frequency of BC worry, and enhance BC prevention knowledge without changing state anxiety. CONCLUSIONS The iPrevent prototype demonstrated good usability and acceptability. Because concerns about length could be an implementation barrier, data entry has been abbreviated in the publicly available version of iPrevent.
- 1 October 2013
- Published by Springer Nature in Familial Cancer
- Vol. 13 (2) , 153-162
Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer
This study assessed the sociodemographic, medical and psychological predictors of accuracy of perceived risk in women at increased genetic risk for ovarian cancer. Women participating in a large cohort study who were at increased risk of ovarian and fallopian tube cancer, had no personal history of cancer and had ≥1 ovary in situ at cohort enrolment, were eligible. Women completed self-administered questionnaires and attended an interview at enrolment. Of 2,868 women unaffected with cancer at cohort enrolment, 561 were eligible. 335 women (59.8 %) overestimated their ovarian cancer risk, while 215 women (38.4 %) accurately estimated their risk, and 10 (1.8 %) underestimated it. Women who did not know their mutation status were more likely to overestimate their risk (OR 1.74, 95 % CI 1.10, 2.77, p = 0.018), as were those with higher cancer-specific anxiety (OR 1.05, 95 % CI 1.02, 1.08, p < 0.001) and/or a mother who had been diagnosed with ovarian cancer (OR 1.98, 95 % CI 1.23, 3.18, p = 0.005). Amongst the group of women who did not know their mutation status, 63.3 % overestimated their risk and the mean perceived lifetime risk of developing ovarian cancer was 42.1 %, compared to a mean objective risk of 6.4 %. A large number of women at increased risk for ovarian cancer overestimate their risk. This is of concern especially in women who are at moderately increased risk only; for this sub-group of women, interventions are needed to reduce potentially unnecessary psychological distress and minimise engagement in unnecessary surgery or screening.
- 1 October 2013
- Published by Springer Nature in Familial Cancer
- Vol. 13 (2) , 153-162
Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer
This study assessed the sociodemographic, medical and psychological predictors of accuracy of perceived risk in women at increased genetic risk for ovarian cancer. Women participating in a large cohort study who were at increased risk of ovarian and fallopian tube cancer, had no personal history of cancer and had ≥1 ovary in situ at cohort enrolment, were eligible. Women completed self-administered questionnaires and attended an interview at enrolment. Of 2,868 women unaffected with cancer at cohort enrolment, 561 were eligible. 335 women (59.8 %) overestimated their ovarian cancer risk, while 215 women (38.4 %) accurately estimated their risk, and 10 (1.8 %) underestimated it. Women who did not know their mutation status were more likely to overestimate their risk (OR 1.74, 95 % CI 1.10, 2.77, p = 0.018), as were those with higher cancer-specific anxiety (OR 1.05, 95 % CI 1.02, 1.08, p < 0.001) and/or a mother who had been diagnosed with ovarian cancer (OR 1.98, 95 % CI 1.23, 3.18, p = 0.005). Amongst the group of women who did not know their mutation status, 63.3 % overestimated their risk and the mean perceived lifetime risk of developing ovarian cancer was 42.1 %, compared to a mean objective risk of 6.4 %. A large number of women at increased risk for ovarian cancer overestimate their risk. This is of concern especially in women who are at moderately increased risk only; for this sub-group of women, interventions are needed to reduce potentially unnecessary psychological distress and minimise engagement in unnecessary surgery or screening.